Literature DB >> 17308065

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

Roberto R Rosato1, Jorge A Almenara, Sarah S Kolla, Sonia C Maggio, Stefanie Coe, Maria S Giménez, Paul Dent, Steven Grant.   

Abstract

The mechanism and functional significance of XIAP and Mcl-1 down-regulation in human leukemia cells exposed to the histone deacetylase inhibitor vorinostat and the cyclin-dependent kinase inhibitor flavopiridol was investigated. Combined exposure of U937 leukemia cells to marginally toxic concentrations of vorinostat and flavopiridol resulted in a marked increase in mitochondrial damage and apoptosis accompanied by pronounced reductions in XIAP and Mcl-1 mRNA and protein. Down-regulation of Mcl-1 and XIAP expression by vorinostat/flavopiridol was associated with enhanced inhibition of phosphorylation of RNA polymerase II and was amplified by caspase-mediated protein degradation. Chromatin immunoprecipitation analysis revealed that XIAP and Mcl-1 down-regulation were also accompanied by both decreased association of nuclear factor-kappaB (XIAP) and increased E2F1 association (Mcl-1) with their promoter regions, respectively. Ectopic expression of Mcl-1 but not XIAP partially protected cells from flavopiridol/vorinostat-mediated mitochondrial injury at 48 h, but both did not significantly restored clonogenic potential. Flavopiridol/vorinostat-mediated transcriptional repression of XIAP, Mcl-1-enhanced apoptosis, and loss of clonogenic potential also occurred in primary acute myelogenous leukemia (AML) blasts. Together, these findings indicate that transcriptional repression of XIAP and Mcl-1 by flavopiridol/vorinostat contributes functionally to apoptosis induction at early exposure intervals and raise the possibility that expression levels may be a useful surrogate marker for activity in current trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17308065     DOI: 10.1158/1535-7163.MCT-06-0562

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  35 in total

1.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

2.  Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  William E Pierceall; Ryan J Lena; Bruno C Medeiros; Noel Blake; Camille Doykan; Michael Elashoff; Michael H Cardone; Roland B Walter
Journal:  Leuk Res       Date:  2014-02-28       Impact factor: 3.156

3.  Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.

Authors:  Makiko Kobayashi; Ikuko Takahashi-Suzuki; Toshiyasu Shimomura; Yoshikazu Iwasawa; Hiroshi Hirai
Journal:  Invest New Drugs       Date:  2010-06-04       Impact factor: 3.850

Review 4.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 5.  Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.

Authors:  Youry Kim; Jenny L Anderson; Sharon R Lewin
Journal:  Cell Host Microbe       Date:  2018-01-10       Impact factor: 21.023

6.  Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.

Authors:  Darcy J P Bates; Bethany L Salerni; Christopher H Lowrey; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

Review 7.  Update on rational targeted therapy in AML.

Authors:  Danielle Shafer; Steven Grant
Journal:  Blood Rev       Date:  2016-02-22       Impact factor: 8.250

8.  Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

9.  Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.

Authors:  Qing Liu; Katherine L Farley; Amy J Johnson; Natarajan Muthusamy; Craig C Hofmeister; Kristie A Blum; Larry J Schaaf; Michael R Grever; John C Byrd; James T Dalton; Mitch A Phelps
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

10.  Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.

Authors:  Yi Liao; Xiaojia Niu; Bailing Chen; Holly Edwards; Liping Xu; Chengzhi Xie; Hai Lin; Lisa Polin; Jeffrey W Taub; Yubin Ge; Zhihui Qin
Journal:  J Med Chem       Date:  2016-08-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.